AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041

PRESS RELEASEAB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL ...
The American Journal of Managed Care

The Promise of Frexalimab in MS Treatment: Part 1

Patrick Vermersch, MD, PhD, joined The American Journal of Managed Care® for an interview on promising data from a phase 2 clinical trial on frexalimab in the treatment of multiple sclerosis (MS) and ...
News Medical

Astrocyte immune memory in multiple sclerosis pathology revealed

Immunological memory - the ability to respond to a previously encountered antigen, or foreign substance, with greater speed and intensity on re-exposure is a hallmark of adaptive immunity. Innate ...
GEN

Bridging the Gap Between Innate and Adaptive Immunity

Our immune system is divided into two main branches: innate and adaptive. Innate immune cells act as a first line of defense, quickly responding to invaders, while adaptive immune cells take a longer ...
The Conversation

Multiple sclerosis: blood test that tracks immune response could be first step in developing better treatments

An estimated 2.8 million people worldwide have multiple sclerosis (MS). This autoimmune condition is the result of the immune system damaging parts of the nerves in the brain and spinal cord, which ...
Pharmabiz

AB Science receives Japanese patent for use of masitinib in progressive forms of multiple sclerosis

AB Science receives Japanese patent for use of masitinib in progressive forms of multiple sclerosis: Paris Friday, January 23, 2026, 14:00 Hrs [IST] AB Science SA, a pharmaceutica ...